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Abstract 
The effect of long chain polyunsaturated fatty acids (PUFA) on cell growth and differentiation was assessed in human premonocytic 
U937 cells. Addition of either 10 /xM arachidonic acid (AA, 20:4n-6), eicosapentaenoic acid (EPA, 20:5n-3) or docosahexaenoic acid 
(DHA, 22:6n-3) resulted in the rapid incorporation of these fatty acids into cellular phospholipids. Their uptake was greatest in the first 2 
h. AA and EPA reached steady-state l vels after 8 h, while levels of DHA increased steadily over 72 h. In parallel, fatty acid metabolites 
derived from AA and EPA, 22:4n-6, 22:5n-6 and 22:5n-3, 22:6n-3, respectively, increased continuously indicating an active fatty acid 
elongation and desaturation. The effects of PUFA on monocytic differentiation were examined in cells which had been enriched with AA, 
EPA or DHA for 8 h and subsequently treated with retinoic acid (RA), 1,25-(OH)z-vitamin D 3 (1,25-D3) , interferon-), (IFN-),) or their 
combinations for 72 h. Growth of differentiating or non-differentiating U937 cells was not affected by enrichment with PUFA. However, 
in cells differentiated with 1,25-D 3 plus IFN-),, prior enrichment with all three PUFA slightly but significantly (P < 0.05) increased the 
expression of the monocytic surface antigens CD1 lb and CD14 and generation of superoxide anion. The data indicate that although n-6 
and n-3 PUFA are rapidly incorporated into phospholipids, they do not affect cell growth. However, enrichment with PUFA increases 
monocytic differentiation of U937 cells when induced most effectively with 1,25-D 3 plus IFN-),. 
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1. Introduction 
Long chain polyunsaturated fatty acids (PUFA) are 
essential components of raembrane phospholipids. They 
determine membrane properties [1-3] and modify signal 
transduction across the cell membrane, as indicated by 
changes in ligand-induced receptor activation and second 
messenger formation after enrichment with n-3 and n-6 
PUFA [4,5]. Furthermore, arachidonic acid (AA) and its 
metabolites have recently been identified as a novel class 
of intracellular second messengers [6]. Formation of AA 
cyclooxygenase, lipoxygenase or cytochrome P450 mono- 
oxygenase metabolites ha,; been implicated to modulate 
expression of growth-related genes and cell growth after 
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mitogenic stimulation in different cells [7-9]. In bone 
marrow cells and in granulocyte-macrophage progenitors, 
cytochrome P450 monooxygenase and lipoxygenase 
metabolites of AA,  respectively, have been suggested to 
regulate erythropoiesis [10] and granulopoiesis [11]. From 
these observations, it is tempting to speculate that the 
cellular content of PUFA might affect cell growth and 
differentiation. 
Among the different cells in culture, human premono- 
cytic U937 cells are widely used to study molecular mech- 
anisms of monocytic differentiation. Treatment of U937 
cells with different agents such as retinoic acid (RA; [12]), 
1,25(OH)2-vitamin D 3 (1,25-D3; [13]) or interferon-3, 
(IFN-7; [ 14]) induces maturation to a monocytic ell type 
with cellular functions characteristic of mature monocytes. 
We therefore used U937 cells to determine the effect of 
enrichment with n-6 and n-3 PUFA on cell growth and 
differentiation. 
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2. Materials and methods 
2. l. Materials 
1,25-dihydroxy vitamin D 3 (1,25-D 3) was a kind gift 
from Dr. Fischer, Hoffmann-La Roche, Basel, Switzerland. 
Human recombinant interferon-y (IFN-y) was from 
Amersham (Braunschweig, Germany). All other reagents 
and tissue culture media were from Sigma (Munich, Ger- 
many). 
2.2. Cell culture 
U937 cells were cultured in RPMI 1640 medium sup- 
plemented with 10% fetal calf serum and 2 mM L-gluta- 
mine at 37°C in a humidified incubator aerated with 5% 
CO 2 and 95% air. For all experiments, cells were seeded at 
a density of 0.2 X 10 6 cells per ml and 10 /xM fatty acids 
were added as indicated. After a period of 8 h to allow for 
incorporation of fatty acids into cellular phospholipids, 
differentiation was induced by addition of either retinoic 
acid (RA; 1 /.tM), 1,25-D 3 (10 nM), IFN-y (100 U/ml)  or 
their combinations. In some experiments, lower concentra- 
tions of the combinations RA (0.1 /zM) plus IFN-T (10 
U/ml)  and 1,25-D 3 (1 nM) plus IFN-T (10 U/ml)  were 
used, as indicated. Experiments were performed after 72 h 
of differentiation unless stated otherwise. 
2.3. Analysis of free fatty acid levels and of the fatty acid 
content in phospholipids and triglycerides 
Levels of free fatty acids and fatty acid content of 
phospholipids and triglycerides were analyzed essentially 
as described elsewhere [15]. In brief, at the times indicated, 
1 X l0  6 cells were washed twice in phosphate-buffered 
saline (PBS) and lipids were extracted with 
chloroform/methanol (2:1, with 0.2% BHT). Lipids were 
separated on aminopropyl-bonded phase Bond-Elut 
columns (Baker, The Netherlands). Lipid fractions were 
sequentially eluted using chloroform/methanol (2:1; 
vol:vol) for triglycerides, diethylether with 2% acetic acid 
for free fatty acids and methanol for phospholipids. Fatty 
acids in phospholipids and triglycerides and free fatty 
acids were transesterified with methanolic HC1 (90 ° C; 60 
min), using 20:2n-6 as an internal standard. After extrac- 
tion with petroleum benzene, fatty acid methyl esters were 
analyzed on a Hewlett-Packard 5890A gas chromatograph 
using a capillary column (J and W Scientific, DB-225, 
Fused Silica 30 m, 0.25 mm ID, 0.15 /xm film) with an 
injection temperature of 90 ° C and increases of 70 ° C per 
min to 200 ° C. Fatty acids were identified according to 
retention times of standard compounds and quantified us- 
ing 20:2n-6 as internal standard. 
2.4. Determination of cell proliferation 
Cells were seeded in 24-well plates (Becton Dickinson 
Labware, Germany) and incubated with fatty acids for 8 h 
prior to addition of RA, 1,25-D3, IFN-y or their combina- 
tions as described above. After 24, 48 and 72 h of differen- 
tiation, cells were washed and cell number was determined 
with a Coulter counter model ZM (Coulter Electronics, 
Germany) 
2.5. Expression of monocytic ell surface antigens 
Expression of cell surface antigens was measured by 
flow cytometry. After differentiation for 72 h with or 
without fatty acids, cells were washed twice with PBS and 
resuspended at a density of 1 X l0  7 cells/ml. For each 
determination, 1 X 10 6 cells were incubated for 60 min at 
room temperature with FITC-conjugated monoclonal anti- 
bodies directed against the CDl lb  or CDI4 epitopes 
(Coulter Electronics, Germany) as described previously 
[16]. FITC-conjugated IgM isotype antibody was used to 
control for unspecific binding. After two washes, 1 x 105 
cells were analyzed by flow cytometry (Becton Dickinson, 
Germany). Data are expressed as the percentage of cells 
staining positive for CD1 lb and CD14. 
2.6. Generation of superoxide anion 
Superoxide anion generation was determined by the 
superoxide dismutase-inhibitable r duction of ferricy- 
tochrome c according to Baud et al. [17]. Cells were 
washed twice in buffer A (Hepes 20 raM, NaC1 145 mM, 
KC1 5 mM, MgC12 0.5 mM, Na2HPO 4 1 mM, Glucose 5 
mM, pH 7.4) and 2.5 X 10 6 cells were incubated in 1 ml 
buffer A, containing 80 nmol ferricytochrome c from 
horse heart (type VI). Paired samples contained 300 units 
of superoxide dismutase from bovine erythrocytes. After 
stimulation with 100 nM phorbol myristate acetate (PMA) 
for 20 min at 37 ° C, cells were pelleted and the absorbance 
of the supernatant was measured at 550 nm in a Uvikon 
930 spectrophotometer (Kontron Instruments, FRG) against 
a paired sample containing superoxide dismutase. Superox- 
ide anion generation was calculated using an extinction 
coefficient of 21.1 nM ~× cm ~ for reduced ferricy- 
tochrome c. Data are presented as nmol of O~- released by 
1 × 10 6 cells in 20 min. 
2.7. Phagocytosis 
Phagocytic activity was determined by flow cytometry 
using the commercial Phagotest ®kit (Orpegen, Germany) 
according to the manufacturer's instructions. In brief, cells 
were washed twice with PBS and resuspended in PBS at a 
density of 5 X 10 6 cells/ml. Cells were incubated with 
fluoresceine isothiocyanate (FITC)-conjugated opsonized 
E. coli in a shaking water bath at 37 ° C for 45 min, while 
control samples were kept on ice. The incubation was 
stopped by placement on ice and addition of a quenching 
solution, followed by three washes with a washing solu- 
tion. The percentage of cells stained positively was deter- 
mined by flow cytometry (Becton Dickinson, Germany). 
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Table 1 
Phospholipid fatty acid composition of U937 cells without and after supplementation with PUFA 
FA (%) Control 10/xM AA 10/xM EPA 10/xM DHA 
8h 72h 8h 72h 8h 72h 
16:0 49.8 + 2.2 44.1 5- 2.1 41.9 5:1.1 41.5 + 1 .l 43.5 + 2.2 43.9 5:2.0 45.4 5:0.9 
18:0 7.4 5:0.5 6.2 _ 0.8 6.0 5:0.7 8.1 5:1.0 7.7 + 0.8 7.9 5:0.7 7.8 5:0.4 
18:1 (n-7) 13.0 + 1.2 11.3 5:0.3 10.6 + 0.7 11.7 + 0.5 9.3 ___ 0.6 14.2 5:1.4 11.3 5:0.6 
18:1 (n-9) 10.6 5:1.3 9.7 ___ 0.8 9.3 ± 0.7 9.9 5:0.7 8.6 + 0.3 11.9 5:0.9 9.1 5:0.8 
18:2 (n-6) 1.3 + 0.2 1.0 _ 0.1 1.0 ± 0.1 1.2 + 0.1 1.0 _ 0.1 1.3 5:0.2 1.0 5:0.1 
20:4 (n-6) 5.1 5:0.3 11.3 5:0.9 a 12.4 + 0.5 a 4.9 + 0.3 4.7 5:0.4 5.8 5:0.3 5.6 5:0.1 
22:4 (n-6) 0.8 + 0.1 2.7 + 0.3 a 5.1 _+ 0.3 a 0.8 + 0.l 0.8 5:0.1 0.8 5:0.1 0.9 5:0.2 
22:5 (n-6) 0.3 5:0.1 0.4 5:0.1 1.5 + 0.1 a 0.3 5:0.1 0.3 5:0.1 0.2 5:0.1 0.3 5:0.1 
20:5 (n-3) 0.3 + 0.06 0.3 + 0.1 0.2 5:0.1 7.4 5:0.5 a 6.1 + 0.3 a 0.6 5:0.1 1.9 5:0.1 a 
22:5 (n-3) 1.1 -t- 0.05 1.1 _ 0.1 1.1 5:0.1 5.0 5:0.1 a 6.9 5:0.4 a 1.2 + 0.1 1.3 5:0.1 
22:6 (n-3) 1.9 5:0.19 1.8 5:0.1 1.9 + 0.1 1.9 5:0.1 3.4 5:0.1 a 6.8 + 0.2 a 8.0 5:0.4 ~ 
n-6 7.4 5:0.4 15.4 5:0.3 19.2 5:0.3 7.2 5:0.2 6.9 5:0.2 8.2 5:0.4 7.7 _ 0.2 
n-3 3.3 5:0.1 3.1 5:0.1 3.2 -]- 0.1 14.3 5:0.3 16.3 ± 0.3 8.5 5:0.1 11.2 5:0.2 
n-6/n-3 2.3 5:0.2 4.9 5:0.2 5.9 5:0.2 0.5 5:0.1 0.4 5:0.1 1.0 _ 0.1 0.7 + 0.1 
Phospholipid fatty acids were analyzed in undifferentiated U937 cells (Control) and in cells enriched with AA, EPA or DHA for 
Values present means + S.D. of three independent determinations. 
a p < 0.01 when compared to the level of the respective PUFA in cells treated with the vehicle ethanol alone (Control). 
the times indicated. 
2.8. Statistical analysis 
Data were tested for sta~tistically significant differences 
using Student's t-test for paired samples and a P-level of 
< 0.05 was considered to indicate statistically significant 
differences. 
3. Results 
3.1. Incorporation of polyunsaturated fatty acids into cel- 
lular phospholipids of U937 cells 
The phospholipid fatty acid profile of untreated cells 
revealed that U937 cells contain low levels of n-6 and n-3 
PUFA (Table 1). Addition of either 10 /zM AA, EPA or 
DHA to the culture medium was followed by rapid incor- 
poration of the respective PUFA into cellular phospho- 
lipids (Fig. 1). For all three PUFA, incorporation was 
greatest in the first 2 h. Phospholipid content of AA and 
EPA reached steady-state l vels at as early as 8 h after 
addition (Table 1). In cells supplemented with DHA, the 
phospholipid content of DHA and its retroconversion prod- 
uct EPA increased steadily over 72 h. In parallel, the 
elongase and desaturase metabolites of AA (22:4n-6 and 
22:5n-6) and EPA (22:5n-3 and 22:6n-3) increased over 72 
h, indicating an active metabolism of PUFA (Table 1). 
PUFA from both the n-6 and n-3 series were incorporated 
at the expense of saturated (16:0 and 18:0) and monounsat- 
urated (18:1n-7 and 18:1n-9) fatty acids, but had no recip- 
rocal effect on each other. 
Table 2 
Triglyceride fatty acid composition of U937 cells without and after supplementation with PUFA 
FA (%) Control 10/xM AA 10/xM EPA 10/zM DHA 
8h 72h 8h 72h 8h 72h 
16:0 36.9 + 4.4 12.9 + 1.4 28.5 -]- 0.3 14.7 + 1.1 32.4 5:0.1 19.9 5:2.3 26.5 5:2.0 
18:0 12.9 -I- 1.6 2.4 + 0.3 7.3 _+ 1.1 2.4 + 0.1 8.6 5:0.8 5.4 5:0.3 7.8 5:0.4 
18:1 (n-7) 20.6+1.5 12.3+1.0 20.85:2.4 15.0+1.2 22.1+1.5 20.15:1.1 20.1+1.2 
18:1 (n-9) 14.0 + 2.9 6.6 + 0.8 12.2 :k 0.6 7.2 + 0.8 15.0 5:1.3 7.4 5:0.7 9.9 5:1.3 
18:2 (n-6) 2.0 _ 0.4 2.4 -I- 0.1 2.9 5:0.1 2.8 5:0.2 2.5 5:0.2 2.7 5:0.3 3.6 5:0.4 
20:4 (n-6) 1.2 5:0.2 39.0 5:4.6 a 1.4 5:0.2 3.6 5:0.9 0.9 5:0.2 1.8 5:0.2 1.2 + 0.2 
22:4 (n-6) 0.7 5:0.1 16.0 5:1.8 a 13.3 5:0.9 a 1.2 5:0.3 1.3 5:0.3 1.2 5:0.2 1.3 + 0.3 
22:5 (n-6) 0.2 5:0.1 1.4 5:0.3 a 2.6 5:0.6 a 0.2 5:0.1 0.3 5:0.1 0.3 5:0.1 0.3 5:0.1 
20:5 (n-3) 0.8 5:0.1 0.3 5:0.1 0.2 5:0.1 19.4 5:2.7 a 1.6 + 0.2 a 0.5 5:0.1 0.6 5:0.0 
22:5 (n-3) 0.8 5:0.2 1.5 +__ 0.2 1.3 + 0.2 25.2 5:3.2 a 10.4 5:1.6 a 2.3 5:0.2 2.0 5:0.4 
22:6 (n-3) 1.1 5:0.2 1.5 5:0.3 1.2 5:0.1 3.7 + 0.5 a 3.0 + 0.4 a 36.2 5:1.8 a 22.5 + 2.3 
n-6 4.1 5:0.2 58.8 5:2.5 20.2 5:0.5 7.8 5:0.6 5.0 5:0.2 6.0 + 0.2 6.4 5:0.3 
n-3 2.7 5:0.1 3.3 + 0.2 2.7 5:0.1 48.3 5:2.1 16.3 5:0.3 39.0 + 0.7 25.1 + 1.3 
n-6/n-3 1.5 5:0.2 17.8 + 1.7 7.5 5:0.3 0.2 + 0.0 0.3 _ 0.1 0.1 _ 0.0 0.2 5:0.0 
Triglyceride fatty acids were analyzed in undifferentiated U937 cells (Control) and in cells enriched with AA, EPA or DHA for the times indicated. Values 
present means + S.D. of three independent determinations. 
a p < 0.01 when compared to the level of the respective PUFA in cells treated with the vehicle ethanol alone (Control). 
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Table 3 
Effect of AA, EPA and DHA on cell growth of differentiating and non-differentiating U937 cells 
cells per ml (× 103) 
Treatment w/o  FA + 10/zM AA + 10/zM EPA + 10/xM DHA 
Control 1765 5- 62 1690 + 71 1695 5- 53 1723 + 89 
RA 1755 + 52 1687 + 63 1703 + 77 1713 5- 121 
1,25-D 3 1817 + 113 1803 _ 78 1811 ± 62 1785 ± 47 
IFN-y 1422 _+ 63 ~ 1374 ± 48 1389 ± 55 1397 ± 81 
RA + IFN-T 1205 + 52 a 1188 5- 39 1170 5- 51 1179 ± 88 
1,25-D 3 + IFN-y 1150 ± 35 a 1130 ± 44 1100 _+ 27 1203 ± 95 
Cells were enriched with either AA, EPA, DHA for 8 h prior to treatment with RA (1 /xM), 1,25-D 3 (10 nM), IFN-T (100 U/ml), their combinations or
their vehicle (ethanol; Control) for 72 h. Data represent mean 5- S.D. of three independent experiments. 
a Reductions in cell numbers were significant at a P-level of < 0.01 when compared to the respective Control conditions, but did not differ significantly 
when compared to treatment with different PUFA. 
In contrast o phospholipid fatty acid content, cellular 
triglyceride levels of AA, EPA, DHA and their respective 
elongation/desaturation or retroconversion metabolites 
markedly increased only during the first 8 h of enrichment. 
Thereafter, PUFA content in triglycerides steadily declined 
until 72 h, although being still higher as compared to 
baseline values (Table 2). Cellular free fatty acid levels 
transiently increased by only l -3% after 8 h and returned 
to baseline values after 72 h (data not shown). All in all, 
more than 70% of the PUFA added were incorporated into 
cellular lipids. 
Given that steady-state l vels of AA and EPA were 
already reached after 8 h and that specific rapidly enriched 
pools of AA may be important for eicosanoid formation 
and cell signaling [18], enrichment with PUFA for 8 h was 
considered adequate to evaluate their effect on cell growth 
and differentiation. 
In differentiating cells, kinetics of PUFA incorporation 
and phospholipid levels of AA, EPA, DHA and their 
metabolites were comparable to undifferentiated cells (data 
not shown). Furthermore, in differentiated cells which had 
not been enriched with PUFA, levels of AA and DHA 
increased by about 10 and 20%, respectively, (data not 
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Fig. 1. Time course of fatty acid incorporation i to phospholipids of 
U937 cells. AA ( • ), EPA (0 )  or DHA (O), 10/xM each, were added to 
the culture medium for the times indicated and phospholipid fatty acids 
determined as detailed in Section 2. Data present means 5- S.D. of three 
separate xperiments, each performed in duplicate. 
shown), supporting our recent observation that differentia- 
tion of premonocytic MonoMac6 and U937 cells is accom- 
panied by increased fatty acid desaturation (NH; unpub- 
lished data). 
3.2. Effect of PUFA enrichment on growth of U937 cells 
Treatment with IFN-T alone or in combination with RA 
or 1,25-D 3 reduced cell number by 20, 32 and 35% 
(P< 0.01), respectively, whereas treatment with RA or 
1,25-D 3 alone had no effect on cell growth (Table 3). 
Enrichment with AA, EPA or DHA did not influence cell 
growth in differentiating or non-differentiating cells (Table 
3). 
3.3. Effect of PUFA enrichment on expression of mono- 
cytic surface antigens in differentiated U937 cells 
Expression of the monocytic surface antigens CD1 lb 
and CD14 was analyzed to evaluate monocytic differentia- 
tion. Treatment with RA or 1,25-D 3 alone or in combina- 
tion with IFN-y markedly increased CDl lb expression, 
whereas IFN-y alone had no effect (Table 4). Expression 
of CD14, however, increased significantly only after dif- 
ferentiation with 1,25-D 3 plus IFN-y. 
Table 4 
Effect of cell differentiation on expression of CD1 lb and CDI4 
Percent of cells staining positive 
Treatment CD 11 b CD 14 
Control 1.4 + 0.8 0.5 + 0.3 
RA 47.3+3.5 a 0.4+0.2 
1,25-D 3 48.1 +2.1 ~ 2.8-t- 1.0 
IFN-T 3.8 _+ 0.6 0.5 + 0.2 
RA + IFN-T 63.3 ± 5.4 a 0.5 + 0.4 
1,25-D 3 +IFN-T 77.8+3.5 a 27.05- 1.7 a 
Cells were treated with RA (1 /zM), 1,25-D 3 (10 nM), IFN-y (100 
U/ml), their combinations or their vehicle ethanol (Control) for 72 h. 
Expression of CD1 lb and CD14 was determined by flow cytometry. Data 
present he percentage of cells staining positive for the respective anti- 
gens (mean + S.D. from three independent experiments). 
a p < 0.01 when compared to the respective Control. 
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Enrichment with PUFA enhanced expression of CD1 lb 
and CD1 lb/CD14 only in cells treated with 1,25-D 3plus 
RA and 1,25-D 3plus IFN-,y, respectively. When differen- 
tiated with 10 nM 1,25-D 3 plus 100 U/ml IFN-'y, enrich- 
ment with AA, EPA or DHA increased expression of 
CD14 by 33, 30 and 44% (Table 5), respectively, whereas 
the percentage of cells staining positive for CDllb was 
only slightly higher (7-16%; Table 6). In parallel, in cells 
treated with 1 /xM RA plus 100 U/ml IFN-3,, enrichment 
with AA, EPA or DHA marginally increased expression of 
CDllb by 5-9%. However, the effect of AA, EPA or 
DHA on CDllb expression became evident when cells 
Table 5 
CDI4 expression and induction of superoxide anion generation i  U937 cells differentiated with 1,25-D 3 plus IFN-? after enrichment with fatty acids 
Fatty acid CD 14 expression O~- generation 
added Positive cells Relative nmol/1 )< 106 cells/ Relative 
[%] increase 20 min increase 
Control 30.6 :_~ 2.4 10.3 + 0.7 
16:0 34.2 :k 3.9 11% n.e. n.e. 
18:2 39.5 ± 5.7 29% a n.e. n.e. 
20:4 40.9 ± 2.9 34% b 15.4 ± 1.3 50% b 
20:5 42.5 ± 3.2 39% ~ 14.0 + 1.2 36% a 
22:6 43.9 :h 3.2 43% b 12.5 ± 0.5 21% a 
Cells were enriched with the fatty acid indicated or ethanol (Control) for 8 h prior to treatment with 1,25-D 3 (10 nM) plus IFN-T (100 U/ml)  for 72 h. 
Expression of CD14 was determined by flow cytometry and of superoxide anion generation as detailed in Section 2. Data represent the mean 5: S.E.M. 
from three (02 generation) and five (CD14 expression) independent experiments. 
P < 0.05; 
b p < 0.01, when compared to the: respective Control. 
n.e.: not examined. 
Table 6 
CD1 lb expression i U937 cells differentiated with various concentrations of differentiation-inducing compounds and after enrichment with fatty acids 
Fatty acid 1,25-D 3 + IFN-'y 1,25-D 3 + IFN-',/ RA + IFN-T RA + IFN-T 
added (1 nM + 10 U/ml)  (10 nM + 100 U/ml)  (0.1 /zM + 10 U/ml)  (1 /xM + 100 U/ml)  
Positive Relative Positive Relative Positive Relative Positive Relative 
cells [%] increase cells [%] increase cells [%] increase cells [%] increase 
Control 30.3 5:4.3 77.8 5:3.5 30.4 ± 4.7 63.3 5:5.4 
16:0 32.8 + 4.3 8% a n.e. n.e. 31.0 ± 5.2 2% n.e. n.e. 
18:2 37.0 + 5.0 22% a n.e. n.e. 31.8 ± 4.8 5% n.e. n.e. 
20:4 42.8 + 4.7 41% b 85.5 5:4.1 10% 40.1 ± 4.3 32% a 66.5 ± 3.2 5% 
20:5 43.0 ± 5.6 42% a 83.2 ± 2.8 7% 38.1 ± 4.5 25% a 67.1 ± 4.3 6% 
22:6 43.1 ± 5.5 42% a 90.2 ± 5.1 16% b 41.4 ± 5.2 36% a 69.0 ± 4.7 9% 
Cells were enriched with the fatty acid indicated or ethanol (Control) for 8 h prior to treatment for 72 h with 1,25-D 3 plus IFN- 7 or RA plus IFN-? at the 
low or high concentrations indicated. Data represent mean + S.E.M. of five independent experiments with low concentrations and of three independent 
experiments with high concentrations. 
a p < 0.05; 
b p < 0.01, when compared to the respective condition without addition of PUFA. 
n.e.: not examined. 
Table 7 
Effect of AA, EPA and DHA on phagocytosis of opsonized Escherichia col± 
Percent of cells staining positive for phagocytosed E. col± 
Treatment w/o  FA AA EPA DHA 
Control 16.3 + 2.7 16.5 + 2.6 16.5 + 2.5 16.4 + 2.5 
RA 24.8 + 4.8 27.0 + 2.8 25.2 + 8.3 25.4 + 5.8 
1,25-D 3 30.1 + 4.8 31.3 ± 5.0 31.6 + 5.7 33.6 4- 5.7 
IFN-3, 12.3 ± 2.3 12.3 ± 1.7 12.6 + 4.1 12.4 -t- 1.8 
IFN-y + RA 17.6 + 2.2 21.9 + 1.1 a 20.5 + 1.8 a 22.7 5:2.9 a 
IFN-'y + 1,25-D 3 22.4 ± 1.8 25.9 5:2.2 a 27.6 5:2.8 a 28.4 + 4.7 b 
Cells were enriched with either/LA, EPA, DHA for 8 h prior to treatment with RA (1 p-M), 1,25-D 3 (10 nM), IFN-',/(100 U/ml), their combinations or
their vehicle ethanol (Control) fo'r 72 h. Data represent mean ± S.D. of 3 (CTRL, RA, IFN-~/) or 5 (1,25-D 3, RA + IFN-),, 1,25-D 3 + IFN-3,) independent 
experiments. 
a p < 0.05; 
b p < 0.01, when compared to the respective condition without addition of PUFA. 
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were treated with lower concentrations of RA plus IFN-y 
or 1,25-D 3 plus IFN-y. Enrichment with AA, EPA or 
DHA increased the percentage of cells staining positive for 
CD1 lb by 34, 31 and 38%, respectively, when treated with 
100 nM RA plus 10 U/ml  IFN-T and by 43, 48 and 50% 
(Table 6), respectively, when treated with 1 nM 1,25-D 3 
plus 10 U/ml IFN-y. In addition to AA, EPA and DHA, 
enrichment with linoleic acid (18:2n-6) also increased 
expression of CD14 and CD1 lb, although to a smaller 
degree, whereas palmitic acid (16:0) had no effect on 
surface antigen expression. 
3.4. Effect of  PUFA enrichment on superoxide anion gen- 
eration and phagocytosis in differentiated U937 cells 
Generation of superoxide anion and phagocytic activity 
were determined as functional markers of differentiated 
cells. Induction of NADPH oxidase activity was observed 
only after treatment with 1,25-D 3 or RA plus IFN-T (data 
not shown). In cells differentiated with 1,25-D 3 plus IFN-T, 
enrichment with AA, EPA or DHA increased O~- genera- 
tion after stimulation with PMA by 49, 36 and 21%, 
respectively (Table 5). 
Phagocytosis was greatest in cells treated with 1,25-D 3, 
while IFN-T reduced phagocytic activity (Table 7). Inhibi- 
tion of phagocytosis by IFN-y was also evident when used 
in combination with RA or 1,25-D 3, contrasting the effect 
of these combinations on surface antigen expression. En- 
richment with PUFA increased the number of phagocytic 
cells only moderately, with significant changes being ob- 
served after treatment with RA plus IFN-T or 1,25-D 3 
plus IFN-T. In both conditions, AA, EPA and DHA en- 
hanced phagocytic activity by about 20% (Table 7). In 
untreated cells and in cells treated with RA, 1,25-D 3 or 
IFN-y alone, PUFA did not significantly affect phago- 
cytosis (Table 7). 
4. Discussion 
Supplementation with AA, EPA or DHA resulted in 
their rapid and continuous incorporation i to cellular phos- 
pholipids. AA and EPA were metabolized by elongase and 
desaturase enzymes, as reflected by the increasing levels of 
22:4n-6, 22:5n-6 and 22:5n-3, 22:6n-3, respectively. En- 
richment with DHA also gradually increased the content of 
EPA, indicating retroconversion of DHA to EPA. Re- 
cently, rapid incorporation of AA and EPA into phospho- 
lipids and metabolism by elongase and desaturase enzymes 
have also been found in premonocytic THP-1 cells [19]. 
Since cells grown in culture generally have low phospho- 
lipid leVels of long chain PUFA [19,20], our data suggest 
that these cells may quite avidly replenish their phospho- 
lipid pools. In contrast o in vivo studies [21], n-6 or n-3 
PUFA were not incorporated at the expense of other long 
chain PUFA, but only reduced the levels of saturated and 
monounsaturated fatty acids. 
The significant increases in cellular phospholipid levels 
of AA, EPA and DHA after supplementation did not affect 
growth of U937 cells. This is at variance to some previous 
reports on growth modulatory effects of n-3 and n-6 
PUFA, although both, stimulatory and inhibitory effects 
have been observed [22-25]. In premonocytic cells, AA 
and EPA increased the growth of untreated THP-1 cells 
[19], while DHA enhanced the growth-inhibitory and dif- 
ferentiation-inducing activity of RA in HL-60 cells [26]. 
Although these observations suggest hat stimulatory or 
inhibitory effects of PUFA on cell growth depend on 
whether cells are induced to differentiate, we did not 
observe such a distinct effect in our strain of U937 cells. 
Furthermore, our data suggest that phospholipid PUFA 
need not be replenished for optimal growth of cells with 
low PUFA levels, as has been recently proposed for THP-1 
cells [19]. 
In contrast to their lack of effect on cell growth, 
enrichment with AA, EPA or DHA increased monocytic 
surface antigen expression in U937 cells treated with 
1,25-D 3 plus IFN-T, the most effective treatment to induce 
monocytic differentiation i this study, as well as in cells 
treated with RA plus IFN-T. Our results indicate that these 
PUFA had a similar effect on differentiation, as demon- 
strated by their almost uniform stimulation of CDI4 and 
CD1 lb expression. Since palmitic acid had no and linoleic 
acid a smaller effect on surface antigen expression, it is 
suggested that AA, EPA and DHA affect differentiation by 
common properties, such as their high chain length and 
degree of unsaturation. PUFA might facilitate intracellular 
signaling involved in the differentiation response to IFN-T, 
in analogy to the AA-dependent activation of the inter- 
feron-stimulated response lement (ISRE) in cells treated 
with IFN-ol [27]. PUFA may also modulate cell differentia- 
tion by increasing protein kinase C activity [28] (also, HO, 
unpublished ata), the key enzyme activated in phorbol 
ester-induced monocytic differentiation of U937 cells [29]. 
Furthermore, it is tempting to speculate that PUFA might 
affect the transcription of distinct genes involved in cell 
differentiation, in analogy to their effect on genes coding 
for enzymes of fatty acid metabolism. Accordingly, AA 
and DHA have been found to stimulate the promoter of the 
acyl-CoA oxidase gene, an enzyme required for fatty acid 
/3-oxidation, via activation of the peroxisome proliferator 
activated receptor (PPAR) [30], a transcription factor of the 
steroid hormone receptor superfamily [31]. To mediate this 
effect of PUFA, PPAR heterodimerizes with another mem- 
ber of the steroid hormone receptor family, the retinoid X 
receptor /3 (RXR/3; [30]) which can be activated by RA 
[32]. Thus, an interaction of PUFA-induced transcription 
factors with RA- or 1,25-D3-activated transcription factors 
may possibly facilitate the expression of differentiation-re- 
lated genes. Alternatively, the rapid enrichment of cells 
with PUFA, known to modulate biochemical and physical 
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membrane properties after incorporation into phospho- 
lipids [1], may also reflect the need for higher levels of 
long chain PUFA in differentiated cells to support mem- 
brane-related monocytic functions. 
In contrast o CD14 expression, the increase in 02 
generation i  cells differentiated with 1,25-D 3 plus IFN-T 
was more fatty acid specific and was highest after enrich- 
ment with AA. Enrichment with PUFA may act to stimu- 
late NADPH oxidase activity. AA has been identified as an 
essential amphiphilic ofacl:or for activation [33-35] and 
maintenance of NADPH oxidase activity [36-38]. Indeed, 
AA added directly to differentiated and PMA-stimulated 
U937 cells, increased O~- generation to a similar extent as 
when incorporated into celhdar phospholipids (HO; unpub- 
lished data). Furthermore, since expression of the genes 
encoding for the p47 and gp91 subunits of NADPH oxi- 
dase was not affected by en;ichment with AA (HO; unpub- 
lished data), PUFA do not appear to increase the differenti- 
ation-induced synthesis of NADPH oxidase. The smaller 
increases in 02 generation seen after enrichment with 
EPA or DHA may reflect he lower capacity of these fatty 
acids as compared to AA to stimulate protein kinase C 
[39], one of the key enzymes of NADPH oxidase activa- 
tion [40]. Alternatively, as continuous release of AA is 
required to maintain NADF'H oxidase activity by an as yet 
unidentified mechanism [37,38], n-3 PUFA may be less 
effective mediators for this process as compared to AA. 
In summary, the data indicate that enrichment of cellu- 
lar phospholipids with AA, EPA or DHA did not affect 
cell growth but increased ifferentiation of U937 cells in 
response to 1,25-D 3 plus IFN-T. We suggest hat the 
enrichment with long chain PUFA modifies cell mem- 
branes to support he expression of differentiation-related 
responses. Therefore, since cultured cells generally have 
low levels of PUFA, they should be supplemented to
optimize the induction of differentiation-related responses. 
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